These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22806944)

  • 1. Reversible covalent inhibition of a protein target.
    Lee CU; Grossmann TN
    Angew Chem Int Ed Engl; 2012 Aug; 51(35):8699-700. PubMed ID: 22806944
    [No Abstract]   [Full Text] [Related]  

  • 2. Cell biology. Lessons in rational drug design for protein kinases.
    Ahn NG; Resing KA
    Science; 2005 May; 308(5726):1266-7. PubMed ID: 15919981
    [No Abstract]   [Full Text] [Related]  

  • 3. 2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors.
    Costales A; Mathur M; Ramurthy S; Lan J; Subramanian S; Jain R; Atallah G; Setti L; Lindvall M; Appleton BA; Ornelas E; Feucht P; Warne B; Doyle L; Basham SE; Aronchik I; Jefferson AB; Shafer CM
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1592-6. PubMed ID: 24534486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of inhibitors against p90 ribosomal S6 kinase 2 (RSK2) through structure-based virtual screening with the inhibitor-constrained refined homology model.
    Li S; Zhou Y; Lu W; Zhong Y; Song W; Liu K; Huang J; Zhao Z; Xu Y; Liu X; Li H
    J Chem Inf Model; 2011 Nov; 51(11):2939-47. PubMed ID: 21995341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
    Leproult E; Barluenga S; Moras D; Wurtz JM; Winssinger N
    J Med Chem; 2011 Mar; 54(5):1347-55. PubMed ID: 21322567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting protein kinases with selective and semipromiscuous covalent inhibitors.
    Miller RM; Taunton J
    Methods Enzymol; 2014; 548():93-116. PubMed ID: 25399643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors.
    Liao JJ
    J Med Chem; 2007 Feb; 50(3):409-24. PubMed ID: 17266192
    [No Abstract]   [Full Text] [Related]  

  • 8. Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity.
    Kirrane TM; Boyer SJ; Burke J; Guo X; Snow RJ; Soleymanzadeh L; Swinamer A; Zhang Y; Madwed JB; Kashem M; Kugler S; O'Neill MM
    Bioorg Med Chem Lett; 2012 Jan; 22(1):738-42. PubMed ID: 22056746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein kinase inhibitors: insights into drug design from structure.
    Noble ME; Endicott JA; Johnson LN
    Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indolin-2-one p38α inhibitors I: design, profiling and crystallographic binding mode.
    Eastwood P; González J; Gómez E; Vidal B; Caturla F; Roca R; Balagué C; Orellana A; Domínguez M
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4130-3. PubMed ID: 21696951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selectivity assessment of kinase inhibitors: strategies and challenges.
    Luo Y
    Curr Opin Mol Ther; 2005 Jun; 7(3):251-5. PubMed ID: 15977423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finding protein kinase hits using structural information.
    Cherry M; Reader J; Williams D
    Prog Med Chem; 2006; 44():1-63. PubMed ID: 16697894
    [No Abstract]   [Full Text] [Related]  

  • 13. Toward a pharmacophore for kinase frequent hitters.
    Aronov AM; Murcko MA
    J Med Chem; 2004 Nov; 47(23):5616-9. PubMed ID: 15509160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The design, annotation, and application of a kinase-targeted library.
    Xi H; Lunney EA
    Methods Mol Biol; 2011; 685():279-91. PubMed ID: 20981529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance.
    Klüter S; Simard JR; Rode HB; Grütter C; Pawar V; Raaijmakers HC; Barf TA; Rabiller M; van Otterlo WA; Rauh D
    Chembiochem; 2010 Dec; 11(18):2557-66. PubMed ID: 21080395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
    Bogoyevitch MA; Fairlie DP
    Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structure of MSK1 reveals a novel autoinhibitory conformation for a dual kinase protein.
    Smith KJ; Carter PS; Bridges A; Horrocks P; Lewis C; Pettman G; Clarke A; Brown M; Hughes J; Wilkinson M; Bax B; Reith A
    Structure; 2004 Jun; 12(6):1067-77. PubMed ID: 15274926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indole RSK inhibitors. Part 1: discovery and initial SAR.
    Boyer SJ; Burke J; Guo X; Kirrane TM; Snow RJ; Zhang Y; Sarko C; Soleymanzadeh L; Swinamer A; Westbrook J; Dicapua F; Padyana A; Cogan D; Gao A; Xiong Z; Madwed JB; Kashem M; Kugler S; O'Neill MM
    Bioorg Med Chem Lett; 2012 Jan; 22(1):733-7. PubMed ID: 22100312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crystal structures and inhibitors of proteins involved in IL-2 release and T cell signaling.
    Brown K; Cheetham GM
    Vitam Horm; 2006; 74():31-59. PubMed ID: 17027510
    [No Abstract]   [Full Text] [Related]  

  • 20. Electrophilic fragment-based design of reversible covalent kinase inhibitors.
    Miller RM; Paavilainen VO; Krishnan S; Serafimova IM; Taunton J
    J Am Chem Soc; 2013 Apr; 135(14):5298-301. PubMed ID: 23540679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.